Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, will be presenting at two scientific conferences in November: the CNS Summit 2023 and the 2023 Neuroscience Education Institute (“NEI”) Congress. According to the announcement, positive top-line results from fasedienol (PH94B) phase 3 PALISADE-2 trial in social anxiety disorder (“SAD”) will be presented by SAD expert, Dr. Michael Liebowitz, at the CNS Summit 2023. The summit will be held on Nov. 10, 2023, and Vistagen’s presentation is slated to begin at 12 p.m. ET. At the NEI event, positive results from PH80 phase 2A study in women diagnosed with vasomotor symptoms (hot flashes) due to menopause will be presented via poster presentations 109, 49 and 89. NEI is also held on Nov. 10, 2023. “Vistagen’s presentations highlight the significant progress we have made to advance new therapies to address urgent unmet patient needs,” said Vistagen CEO Shawn Singh in the press release. “We look forward to initiating our PALISADE-3 phase 3 clinical trial in social anxiety disorder early next year.”
To view the full press release, visit https://ibn.fm/V2EMf
About Vistagen Therapeutics Inc.
Vistagen Therapeutics is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The company is advancing therapeutics with the potential to be faster acting and with fewer side effects and safety concerns than treatments that are currently available for treatment of anxiety, depression and multiple CNS disorders. Vistagen’s pipeline includes six clinical-stage product candidates, including fasedienol (“PH94B”), itruvone (“PH10”), PH15, PH80 and PH284, each an investigational agent belonging to a new class of drugs known as pherines, as well as AV-101, which is an oral prodrug antagonist of the N-methyl-D-aspartate receptor (“NMDAR”). Pherines are neuroactive nasal sprays designed with an innovative and differentiated proposed mechanism of action (“MOA”) that activates chemosensory neurons in the nasal cavity and can beneficially impact key neural circuits in the brain without systemic absorption or direct activity on neurons in the brain. Vistagen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety, depression and several other CNS disorders. For more information about the company, please visit www.Vistagen.com.
NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
InvestorWire is powered by IBN